Companies / Protalix BioTherapeutics, Inc. / Activity
Activity — Protalix BioTherapeutics, Inc.
9 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q1 2026 as of | Mak Capital One LLC 13F manager | New | Common stock | $7.69M | +3.5M | 3,544,139 4.40% of shares | medium |
| Q2 2026 as of | WINTON GROUP Ltd 13F manager | New | Common stock | $130.5K | +56K | 56,001 0.07% of shares | low |
| Q1 2026 as of | AQR Capital Management, LLC 13F manager | New | Common stock | $66.2K | +30K | 30,493 0.04% of shares | low |
| Q1 2026 as of | Two Sigma Investments, LP 13F manager | New | Common stock | $39.3K | +18K | 18,129 0.02% of shares | low |
| Q1 2026 as of | Voya Investment Management LLC 13F manager | New | Common stock | $24.9K | +11K | 11,494 0.01% of shares | low |
| Q1 2026 as of | Prudential Financial Inc 13F manager | New | Common stock | $21.9K | +10K | 10,110 0.01% of shares | low |
| Q1 2026 as of | C M Bidwell & Associates Ltd 13F manager | New | Common stock | $512 | +236 | 236 <0.01% of shares | low |
| Q1 2026 as of | Northwestern Mutual Wealth Management Co 13F manager | New | Common stock | $217 | +100 | 100 <0.01% of shares | low |
| Q1 2026 as of | MAI Capital Management 13F manager | New | Common stock | $63 | +29 | 29 <0.01% of shares | low |